Effect of Tamoxifen and Radiotherapy in Women with Ductal Carcinoma in Situ
Author Information
Author(s): Jack Cuzick, Ivana Sestak, Sarah E Pinder, Ian O Ellis, Sharon Forsyth, Nigel J Bundred, John F Forbes, Hugh Bishop, Ian S Fentiman, William D George
Primary Institution: Cancer Research UK, Centre for Epidemiology, Mathematics, and Statistics, Queen Mary School of Medicine and Dentistry, University of London
Hypothesis
Does radiotherapy and tamoxifen reduce new breast events in women with ductal carcinoma in situ?
Conclusion
Radiotherapy significantly reduces the incidence of new breast events, and tamoxifen also provides benefits in reducing local and contralateral new breast events.
Supporting Evidence
- Radiotherapy reduced the incidence of all new breast events.
- Tamoxifen reduced the incidence of recurrent ipsilateral DCIS and contralateral tumors.
- An absolute 10-year reduction of 6.5% for all new breast events was achieved with tamoxifen.
Takeaway
This study shows that women with a certain type of breast cancer can have fewer new cancer events if they receive radiotherapy and tamoxifen after surgery.
Methodology
Women with completely locally excised DCIS were randomly assigned to receive radiotherapy, tamoxifen, both, or no treatment in a 2x2 factorial trial.
Potential Biases
Potential bias due to elective treatment choices and lack of blinding.
Limitations
No data on adverse events except cause of death were collected.
Participant Demographics
Majority of participants were women aged 50-64 years.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI 0.30–0.56
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website